PeptideStack
5.2kquestions
20kanswers
220users

What did FLOW do with participants who could not tolerate a step?

Asked 25 May 2026Modified 21 days agoViewed 6k times
11

My records go back to the first dose with dates, so I can reconstruct the timeline exactly.

I have read the primary source rather than the summary, which has left me with more questions.

I understand the headline. I do not understand the footnotes, and the footnotes look important.

What can I legitimately conclude from this figure?

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

14 questions
shareeditfollowflag
RI
askedrukhsana_iqbal14k2825 May 2026
Have you seen anything published on this, or is it inference from the mechanism? – Dr_Sara_Kuusela 2 months ago
8Useful. I have added the accept threshold suggestion to my own notes. – Dr_Yusuf_Adeyemi 6 days ago
add a comment

3 Answers

Accepted answer first, then by votes
8

Accepted answer

On the detail: answering this requires distinguishing the maximum studied dose from the maximum useful dose. The trials established the former. The latter is a per-person question that the trials were not designed to answer.

Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.

Concretely, extending the interval and reducing the dose are not equivalent manoeuvres. Reducing the dose lowers the whole concentration-time curve proportionally. Extending the interval lowers the average but deepens the trough, and for a compound whose effect on appetite tracks concentration, a deep trough is felt.

SURMOUNT-1 used a twenty-week escalation of tirzepatide in 2.5 mg increments to maintenance doses of 5, 10 and 15 mg weekly, and reported a clear dose-response across those maintenance levels — which is the closest thing to evidence that the top of the ladder does more than the middle.

The limitation of all trial-derived dosing reasoning is that trial populations were selected, monitored and supported in ways that do not resemble anyone reading this.

Write down in advance what would make you hold a step, because deciding that in the middle of a bad week is not when you are at your most analytical.

edited 9 Jul 2026 by Dr_Priya_Raghunathan — added a caveat about sampling

shareimprove this answerflag
DR
answered · acceptedDr_Priya_Raghunathan94k24830 Jun 2026
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
3

Put another way, the steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.

Holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

More usefully, the maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.

The label instructions for a missed weekly dose differ between agents, and reading the actual prescribing information rather than a summary is worth the ten minutes — the thresholds are specific and the reasoning behind them is stated.

Read the actual prescribing information for the agent in question. It is short, specific, and more reliable than any summary of it.

shareimprove this answerflag
PM
answeredp_mkhize41k13826 Jun 2026
4I have seen exactly this failure mode twice and both times it was the diluent. – juan_esquivel 10 months ago
5The distinction between purity and content cannot be repeated often enough here. – Dr_Signe_Baldursdottir 2 months ago
add a comment
1

Stated carefully, four weeks is not a magic number, it is approximately five half-lives, which is the interval over which a weekly compound reaches steady state after a dose change. Escalating faster means escalating onto a rising concentration.

Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.

Where the label ladders differ between agents, the differences track the potency ratio and the tolerability profile rather than anything deeper. It is worth reading the ladders side by side once, because the pattern — small starting dose, four-week steps, a defined maintenance range and a defined maximum — is identical in structure across the class.

The pharmacokinetics of the acylated agonists are well described: absorption from the subcutaneous depot is slow and rate-limiting, the elimination half-life is approximately one week, and steady state is reached in four to five weeks. Every dosing question in this section follows from those three facts.

The short version: four-week steps because that is steady state, and the ladder is about the side effects, not the result.

shareimprove this answerflag
P9
answeredplate_count_9k95k15826 May 2026
Useful. I have added the accept threshold suggestion to my own notes. – coldpack_88 30 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.